As the dominant US medical device market access pathway, the 510(k) premarket notification is the core route for Class II active medical devices entering the US market. The official MDUFA target review timeline is 90 calendar days. However, many domestic enterprises frequently receive AI queries, leading to project hold-ups; in the worst cases, the timeline can stretch to 330 days, severely delaying product launch schedules. This Beijing CMEF open course shares practical experience from an active laser therapy device case, which followed the traditional 510(k) pathway with zero hold-ups and zero queries, achieving SE Substantial Equivalence determination in only 75 days. We organize the end-to-end lessons learned for enterprises planning to enter the US market.
| Dimension | Direct FDA Submission (Traditional 510(k)) | Third-Party GQRS Review |
|---|---|---|
| Review Timeline | Target 90 days, frequent delays in practice | 20–25 days third-party review + 30 days FDA final review, faster overall cadence |
| Cost | Only FDA official user fees | Additional third-party service fee; Small Business Fee Exemption unavailable |
| Communication | Written correspondence with FDA, slow feedback | Dedicated reviewer assigned; deficiencies clarified promptly |
| Scope of Application | Almost all 510(k) devices | Limited to low/medium-risk devices with available predicates; not for high-risk devices |
Key focus areas for active devices: Safety, EMC, biocompatibility, human factors engineering, and software documentation. Software risk level classification:
Mandatory EMC standard: FDA only accepts IEC 60601-1-2 Rev.4 / 4.1; Rev.3 old editions are not recognized.
If the pathway is ambiguous or test plan assumptions are uncertain, a Pre-Sub can be filed in advance to obtain non-binding FDA feedback, lowering the risk of RTA refusal and queries. Tradeoff: extra lead time.
Prioritize predicates cleared in recent years; avoid older K numbers with high adverse event records.
If the primary predicate cannot cover all parameters, supplement with 1–2 reference devices for auxiliary comparison.
The comparison table must align item-by-item: intended use, indications for use, operating environment, technical parameters, biocompatibility, electrical safety, software risk level, accessory configuration. Every item must support the SE/NSE conclusion; documented rationale is required for all parameter differences.
Valid for 1 year, expires automatically every Oct 1. Reapplication required for new projects.
Insufficient predicate selection justification, logical gaps in comparison tables
Incomplete test reports, missing biocompatibility lab qualification attachments
Conflicting intended use between labeling and IFU; missing Rx-only marking
Conflicting descriptions across device sections and reports
Inadequate biocompatibility justification; product name mismatch between report and submission
Missing software and cybersecurity risk assessment
Unassessed electromagnetic environment risks (MRI, magnet spacing)
Errors in UDI format, date format, manufacturer address information
Cross-check all versions of IFU and labeling; distinguish OTC / Rx markings
Include full biocompatibility reports and lab qualification certificates in the submission package
Complete software risk management: identify all hazards and implement control measures
Add EMC deviation reports, risk controls for special electromagnetic scenarios including MRI / 5G / RFID
Fully output radiation safety reports for active devices
Jan 30: FDA receives submission package, fee verification, eSTAR file intake
Feb 13 (Day 14): Submission confirmed complete, enters substantive review
Apr 1 (Day 61): FDA interactive inquiry, no formal query and no hold
Apr 15 (Day 75): Formal SE substantial equivalence granted, project closed